HK1244445A1 - 使用抗-ang2抗体的方法 - Google Patents

使用抗-ang2抗体的方法 Download PDF

Info

Publication number
HK1244445A1
HK1244445A1 HK18103973.5A HK18103973A HK1244445A1 HK 1244445 A1 HK1244445 A1 HK 1244445A1 HK 18103973 A HK18103973 A HK 18103973A HK 1244445 A1 HK1244445 A1 HK 1244445A1
Authority
HK
Hong Kong
Prior art keywords
antibody
cancer
ang
dose
administered
Prior art date
Application number
HK18103973.5A
Other languages
English (en)
Chinese (zh)
Inventor
Dominic Lai
Robert Sikorski
David Hyman
Naiyer A. RIZVI
Original Assignee
Medimmune, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune, Llc filed Critical Medimmune, Llc
Publication of HK1244445A1 publication Critical patent/HK1244445A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18103973.5A 2014-05-07 2015-05-06 使用抗-ang2抗体的方法 HK1244445A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461989884P 2014-05-07 2014-05-07
US61/989884 2014-05-07
US201462005525P 2014-05-30 2014-05-30
US62/005525 2014-05-30
PCT/US2015/029447 WO2015171747A1 (en) 2014-05-07 2015-05-06 Methods of using anti-ang2 antibodies

Publications (1)

Publication Number Publication Date
HK1244445A1 true HK1244445A1 (zh) 2018-08-10

Family

ID=54392949

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103973.5A HK1244445A1 (zh) 2014-05-07 2015-05-06 使用抗-ang2抗体的方法

Country Status (12)

Country Link
US (1) US20170058025A1 (https=)
EP (1) EP3139956A4 (https=)
JP (1) JP2017514854A (https=)
KR (1) KR20170003651A (https=)
CN (1) CN107206067A (https=)
AU (1) AU2015256052A1 (https=)
CA (1) CA2946906A1 (https=)
HK (1) HK1244445A1 (https=)
IL (1) IL248391A0 (https=)
RU (1) RU2016147521A (https=)
SG (1) SG11201609168PA (https=)
WO (1) WO2015171747A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
KR102543878B1 (ko) 2016-08-23 2023-06-14 메디뮨 리미티드 항-ｖｅｇｆ-ａ 및 항-ａｎｇ2 항체 및 이의 용도
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
CA3131250A1 (en) * 2019-02-25 2020-09-03 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN118027319A (zh) 2019-05-08 2024-05-14 大金工业株式会社 含氟聚合物
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009209251B8 (en) * 2008-01-28 2015-03-26 Medimmune Limited Stabilized Angiopoietin-2 antibodies and uses thereof
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US8980268B2 (en) * 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
KR102104197B1 (ko) * 2010-02-23 2020-04-24 제넨테크, 인크. 난소암의 치료를 위한 항혈관신생 요법
CN102250247B (zh) * 2011-06-15 2013-06-19 常州亚当生物技术有限公司 一种抗vegf/ang2双特异性抗体及其应用
BR112014012187A2 (pt) * 2011-11-21 2017-05-30 Motorola Mobility Llc determinação implícita e determinação implícita e explícita combinadas de imagem colocalizada para predição temporal
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma

Also Published As

Publication number Publication date
WO2015171747A1 (en) 2015-11-12
CA2946906A1 (en) 2015-11-12
RU2016147521A (ru) 2018-06-09
CN107206067A (zh) 2017-09-26
EP3139956A4 (en) 2017-11-29
KR20170003651A (ko) 2017-01-09
IL248391A0 (en) 2016-11-30
EP3139956A1 (en) 2017-03-15
JP2017514854A (ja) 2017-06-08
RU2016147521A3 (https=) 2018-12-27
AU2015256052A1 (en) 2016-11-10
SG11201609168PA (en) 2016-12-29
US20170058025A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
HK1244445A1 (zh) 使用抗-ang2抗体的方法
JP7453943B2 (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
Guo et al. Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases
JP6038650B2 (ja) Ｄｌｌ４アンタゴニスト及び化学療法剤を用いたがんの治療方法
CN113195000A (zh) 抗体-药物缀合物和激酶抑制剂的组合
US20250032583A1 (en) IL-10 Monomer Fusion Protein and Use thereof
Krug et al. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma
EP4346904A1 (en) Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
TW201438736A (zh) 以ｄｌｌ４拮抗劑治療卵巢癌之方法
KR20240114759A (ko) 치료
CN119013304A (zh) 在胃癌中使用抗人cd39抗体、抗人pd-1抗体和化疗的组合
US11566045B2 (en) Tumor targeting polypeptide and method of use thereof
JP4955654B2 (ja) 癌の治療のためのｐ２１タンパク質を含んで成るコンジュゲート
US20150290255A1 (en) Pharmaceutical composition for treating cancer
Zhang et al. A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer
CN105120881A (zh) 使用麦胶蛋白肽治疗癌症的套件和方法
JP2026510832A (ja) Ｉｌ－２ ｐｅｇコンジュゲートによる癌療法
WO2026060032A2 (en) Nucleic acids encoding engineered chimeric fusion proteins
CN119300862A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
HK40116183A (zh) 核酸-多肽组合物及其用途
Chan et al. Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
JP2015536909A (ja) 合成ポリヌクレオチド結合ペプチドのファミリーおよびその使用
CN121620393A (zh) 用于治疗癌症的方法和组合物
AU2022389646A1 (en) Combination therapy for cancer
WO2021257961A1 (en) Compositions and methods for treating cancer